炎症性腸疾患(IBD)治療薬の世界市場2016-2026

◆英語タイトル:Inflammatory Bowel Diseases (IBD) 2016-2026
◆商品コード:VGAIN6012611
◆発行会社(調査会社):visiongain
◆発行日:2016年1月
◆ページ数:190
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,799 ⇒換算¥257,257見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥428,857見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥714,857見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、炎症性腸疾患(IBD)治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・炎症性腸疾患(IBD)の概要
・炎症性腸疾患(IBD)治療薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・炎症性腸疾患(IBD)治療薬の世界市場:医薬品別市場分析
・炎症性腸疾患(IBD)治療薬の世界市場:研究開発パイプライン分析
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Inflammatory Bowel Diseases – Your New Guide to Pharma R&D, Opportunities and Revenue Predictions
What does the future hold for drugs treating inflammatory bowel diseases (IBD)? Those intestinal medicines retain high potential. Now you can explore sales forecasts and that industry’s research and development.

Visiongain’s new report predicts those revenues to 2026 at overall world market, submarket, product and national level. There you assess commercial opportunities for therapies treating disorders including Crohn’s disease and ulcerative colitis.

So please read on to examine those colonic treatments, seeing how high that industry’s sales can go. Discover what is possible for that large, expanding market.

Forecasts and other analyses to help your gastrointestinal (GI) drug research, knowledge and influence
Avoid struggles to find that business information. Instead see what is happening in treating those lower digestive tract disorders. Now you can make your research, analysis and decisions on the IBD drugs market quicker and easier.

Besides revenue forecasting to 2026, our new report shows you sales results, growth rates, market shares and discussions. There you gain 93 tables, 42 charts and two interviews with organisations. Stay ahead in knowledge to help your work on IBD.

Forecasting of the overall IBD market and five therapeutic segments
Our study predicts overall world revenue to 2026 for treating those intestinal disorders. There you also find individual revenue predictions for five submarkets at world level:
• Biologics, including monoclonal antibodies (mAbs)
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators.

Discover there how competition and technological advances shape that industry. Also benefit your reputation for commercial insight and see how you can gain. That way you find where the money lies in that progressing, expanding pharma market.

For those lower gut treatments our analyses also investigate leading brands’ prospects.

Forecasts for 17 top products – discover sales potentials
How will leading drugs perform to 2026 at world level? Our study forecasts individual revenues of 17 leading medicines for those colonic disorders, including these agents:
• Humira
• Remicade
• Asacol
• Pentasa
• Lialda
• Tysabri

You also gain sales predictions for these brands:
• Cimzia
• Entocort
• Uceris
• Simponi
• Entyvio

Our study shows how high sales can go, to 2026, revealing medicines and years with highest predicted growth and revenues. Treating large-intestine disease holds much commercial potential. Explore what the future holds for treating inflamed bowel.

You also discover geographical revenue predictions.

Healthcare in national markets – what outlooks for those pharmaceuticals?
Our report shows you individual revenue forecasting to 2026 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

There you find countries with highest IBD revenues, demand and potential sales. Investigate progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that biopharma industry and market? Our new investigation explains.

R&D and other trends influencing those therapies and their producers
Our new analysis explains policies, issues and R&D shaping the IBD drugs industry and market. Assess the effects of these influences:
• IBD diagnosis, incidence and prevalence – see prospects for rising sales
• Monoclonal antibodies (mAbs) and biosimilars (follow-on protein products) – assess their potentials for changing that GI drugs market
• Drug delivery systems – advances in supporting technology
• Competition from generic drugs – see how they can erode that market
• Economic pressures – budgetary limitations in healthcare and therapy costs.

In particular our study discusses research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists.

R&D for IBD holds high potential. Our study shows that pharma segment’s progress and prospects. There you explore what stimulates and restrains that market. Avoid falling behind. Instead see what the future holds and how you can benefit.

Treatments for inflamed lower intestine – top companies and 2019 market value
Our report predicts the overall world market for those products will reach $9.3bn in 2019, with revenue growth from 2016. IBD medicines hold high potential for investments, technologies, medical advances and sales. See what is possible.

That work also explores activities, results and potentials of top companies, especially these firms:
• AbbVie
• Janssen Biotech
• Allergan
• Shire Pharmaceuticals.

With our new study you see how that market can develop and perform, benefiting your insight and authority. Discover how you can help your research, analysis and planning, also benefiting your influence.

【レポートの目次】

1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who Is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2016-2026
3.1 The Inflammatory Bowel Disease Market in 2014 and 2015
3.2 Forecast 2016-2026: Impacted by Biosimilars?
3.3 Biologic Therapies Forecast 2016-2026 – Driving the Market
3.4 Aminosalicylates Forecast 2016-2026: The Work Horse of IBD Market
3.5 Antibiotics Forecast 2016-2026: Growing Despite Challenges
3.6 Corticosteroids Forecast 2016-2026: Driven by Uceris
3.7 Immunomodulators Forecast 2016-2026 – Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2016-2026
4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period
4.1.1 Humira: Forecast and Analysis, 2016-2026
4.2 Remicade (Janssen Biotech) – Will Slowly be Eroded by Biosimilars
4.2.1 Remicade: Forecast and Analysis, 2016-2026
4.3 Asacol (Allergan) – Threat from Generic Competition
4.3.1 Asacol: Forecast and Analysis, 2016-2026
4.4 Pentasa (Shire) – Differentiated by Its Delivery System
4.4.1 Pentasa: Forecast and Analysis, 2016-2026
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2016-2026
4.6Tysabri (Perrigo) – Still Protected by Patent
4.6.1 Tysabri: Forecast and Analysis, 2016-2026
4.7 Xifaxan (Valeant) – Still Growing Significantly
4.7.1 Xifaxan: Forecast and Analysis, 2016-2026
4.8 Cimzia (UCB) – How Will it Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2016-2026
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2016-2026
4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?
4.10.1 Neoral: Forecast and Analysis, 2016-2026
4.11 Medrol (Pfizer) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2016-2026
4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2016-2026
4.13 Apriso (Valeant) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2016-2026
4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market
4.14.1 Azulfidine: Forecast and Analysis, 2016-2026
4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment
4.15.1 Entyvio: Forecast and Analysis, 2016-2026
4.16 Simponi (Janssen Biotech) – Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2016-2026
4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System
4.17.1 Uceris: Forecast and Analysis, 2016-2026

5. Leading National Markets, 2016-2026
5.1 IBD Drugs-Leading National Market 2014
5.2 The US IBD Drug Market, 2016-2026 – The World Leader
5.3 The Japanese IBD Drug Market, 2016-2026 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2016-2026 – Driven by the UK
5.4.1 The German IBD Drug Market, 2016-2026
5.4.2 The French IBD Drug Market, 2016-2026
5.4.3 The UK IBD Drug Market, 2016-2026
5.4.4 The Spanish IBD Drug Market, 2016-2026
5.4.5 The Italian IBD Drug Market, 2016-2026
5.5 IBD Drug Market in BRIC Countries – Taking More Market Share
5.5.1 The Brazilian IBD Drug Market, 2016-2026
5.5.2 The Russian IBD Drug Market, 2016-2026
5.5.3 The Indian Drug Market, 2016-2026
5.5.4 The Chinese IBD Drug Market, 2016-2026

6. The R&D Pipeline for Inflammatory Bowel Disease in 2015
6.1 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.1.1 CyCol (Sigmoid Pharma Limited)
6.1.2 PF-04236921 (Pfizer)
6.1.3 QAX 576 (Novartis)
6.1.4 TNF Kinoid (Neovacs)
6.1.5 Vidofludimus (4SC) – Suspended
6.1.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech, Inc.)
6.2 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.2.1 AJG 511 (Ajinomoto Pharmaceutical Co., Ltd)
6.2.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.2.3 MEDI 7183/AMG 181 (AstraZeneca & Amgen)
6.2.4 Etrolizumab (Roche)
6.2.5 PF-00547659 (Pfizer)
6.2.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.2.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
6.3 TNF-alpha Inhibitors – A Specific Target
6.3.1 AVX-470 (Avaxia Biologics)
6.3.2 Ozoralizumab (ALX-0061, Ablynx)
6.4 Stem Cell Therapies – Basis for a Cure?
6.4.1 Ovasave (TxCell)
6.4.2 MultiStem (Athersys Inc and Pfizer)
6.4.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.4.4 Cx601 (TiGenix)
6.5 JAK Inhibitors – New Target Pathway
6.5.1 JNJ-54781532 (Janssen)
6.5.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.6 Toll-like Receptor Agonists – An Answer for Steroid-Refractory IBD?
6.6.1 BL-7040 (BioLineRX)
6.6.2 Kappaproct (InDex Pharmaceuticals)
6.7 Other Classes of Agent
6.7.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.7.2 GLPG0974 (Galapagos)
6.7.3 RPC1063 (Receptos/Celgene)
6.7.4 SGX203 (Soligenix)
6.7.5 Mongersen (GED-0301, Celgene)
6.7.6 Tetomilast (OPC-6535, Otsuka)
6.7.7 Laquinimod (Active Biotech)
6.7.8 RHB-104 (RedHill Biopharma)
6.7.9 Ozanimod (Celgene)
6.7.10 GED-0301 (Celgene)
6.8 Biosimilar Candidates – Promising Competitors of Leading Biologics
6.8.1 Adalimumab Biosimilars
6.8.2 Infliximab Biosimilars

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2016
7.1 SWOT and STEP Analyses of the IBD Drugs Market
7.2 What Factors Will Drive the IBD Market?
7.2.1 Increasing Disease Incidence in Most National Markets
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems Improve Existing Drugs
7.2.4 Biological Drugs – Driving the Market Significantly
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance – Frequent Dosing is Inconvenient
7.3.3 Limits of Biologics – Side Effect Profiles
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Quality Depends on Time-Decision Making
7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market
8.1 The Largest Companies by Revenue
8.1.1 AbbVie – Current Leader and Continually Expanding
8.1.2 Janssen Biotech – Contender for Future Leader of the Market?
8.1.3 Allergan– Newcomer to the Big Four
8.1.4 Shire Pharmaceuticals – What is its Outlook?

9. Research Interviews
9.1 Dr Didier Merlin, Institute for Biomedical Sciences, Georgia State University
9.1.1 Unmet Needs in the Management of Ulcerative Colitis
9.1.2 Curcumin for the Treatment of Ulcerative Colitis
9.1.3 The Use of Curcumin in Clinical Settings – Limitations and Drawbacks
9.1.4 Colitis-targeting Drug Release
9.1.5 Potential Clinical Efficacy of this Novel Approach
9.2 Dr Lawrence Kosinski, Founder and Chairman of SonarMD, LLC
9.2.1 SonarMD, LLC
9.2.2 SonarMD Platform – Patient Engagement Platform
9.2.3 Differentiated from Other Patient Management Platforms
9.2.4 Development Plans for Further Optimisation
9.2.5 Parameters to Measure Impact in Clinical Settings
9.2.6 SonarMD Platform – Raised Patient Acceptance Rate from 27% to 80%

10. Conclusions of the Study
10.1 The IBD Drugs Market Will Expand from 2016 to 2026
10.2 Aminosalicylates and Other Non-Biologic Treatments
10.3 Biologic Treatments Dominate the Market
10.4 Improvements Needed in IBD Therapy
10.5 Future IBD Treatments: R&D Efforts Look Promising
10.6 The IBD Sector: Looking to the Future with Confidence

List of Tables
Table 1.1 National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2015-2020
Table 1.2 National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2021-2026
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2015
Table 2.3 Worldwide Incidence Rates for IBD, 2015
Table 2.4 Geographical Variations in the Incidence of IBD, 2015
Table 2.5 Other Drug Types Used to Treat IBD, 2015
Table 2.6 Treatment Protocol for IBD, 2015
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2014 and 2015
Table 3.2 Global IBD Drug Market Forecast ($m), 2015-2026
Table 3.3 Global IBD Drug Forecasts by Drug Category ($m), 2015-2026
Table 3.4 Global IBD Drug Market Drivers and Restraints, 2016-2026
Table 3.5 Global Biologics Forecast for IBD Market ($m), 2015-2026
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2016-2026
Table 3.7 Global Aminosalicylates Forecast for IBD Market ($m), 2015-2026
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2016-2026
Table 3.9 Global Antibiotics Forecast for IBD Market ($m), 2015-2026
Table 3.10 Global Antibiotics Drivers and Restraints, 2016-2026
Table 3.11 Global Corticosteroids Forecast for IBD Market ($m), 2015-2026
Table 3.12 Global Corticosteroids Drivers and Restraints, 2016-2026
Table 3.13 Global Immunomodulators Forecast for IBD Market ($m), 2015-2026
Table 3.14 Global Immunomodulators Drivers and Restraints, 2016-2026
Table 4.1 Leading IBD Treatments by Revenue ($m), 2014
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), 2015-2020
Table 4.3 Leading IBD Medicines: Revenue Forecasts ($m), 2021-2026
Table 4.4 World Humira Revenue Forecast ($m), 2015-2026
Table 4.5 Drivers and Restraints for Humira, 2016-2026
Table 4.6 World Remicade Forecast ($m), 2015-2026
Table 4.7 Drivers and Restraints for Remicade, 2016-2026
Table 4.8 World Asacol Forecast ($m), 2015-2026
Table 4.9 Drivers and Restraints for Asacol, 2016-2026
Table 4.10 World Pentasa Forecast ($m), 2015-2026
Table 4.11 Drivers and Restraints for Pentasa, 2016-2026
Table 4.12 World Lialda Forecast ($m), 2015-2026
Table 4.13 Drivers and Restraints for Lialda, 2016-2026
Table 4.14 World Tysabri Forecast ($m), 2015-2026
Table 4.15 Drivers and Restraints for Tysabri, 2016-2026
Table 4.16 World Xifaxan Forecast ($m), 2015-2026
Table 4.17 Drivers and Restraints for Xifaxan, 2016-2026
Table 4.18 World Cimzia Forecast ($m), 2015-2026
Table 4.19 Drivers and Restraints for Cimzia, 2016-2026
Table 4.20 World Entocort Forecast ($m), 2015-2026
Table 4.21 Drivers and Restraints for Entocort, 2016-2026
Table 4.22 World Neoral Forecast ($m), 2015-2026
Table 4.23 Drivers and Restraints for Neoral, 2016-2026
Table 4.24 World Medrol Forecast ($m), 2015-2026
Table 4.25 Drivers and Restraints for Medrol, 2016-2026
Table 4.26 World Canasa Forecast ($m), 2015-2026
Table 4.27 Drivers and Restraints for Canasa, 2016-2026
Table 4.28 World Apriso Forecast ($m), 2015-2026
Table 4.29 Drivers and Restraints for Apriso, 2016-2026
Table 4.30 World Azulfidine Forecast ($m), 2015-2026
Table 4.31 Drivers and Restraints for Azulfidine, 2016-2026
Table 4.32 World Entyvio Forecast ($m), 2015-2026
Table 4.33 Drivers and Restraints for Entyvio, 2016-2026
Table 4.34 World Simponi Forecast ($m), 2015-2026
Table 4.35 Drivers and Restraints for Simponi, 2016-2026
Table 4.36 World Uceris Forecast ($m), 2015-2026
Table 4.37 Drivers and Restraints for Uceris, 2016-2026
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2014
Table 5.2 Global IBD Drug Market Forecasts by Leading Country ($m), 2015-2020
Table 5.3 Global IBD Drug Market Forecasts by Leading Country ($m), 2021-2026
Table 5.4 US IBD Drug Market Forecast ($m), 2015-2026
Table 5.5 Japanese IBD Drug Market Forecast ($m), 2015-2026
Table 5.6 EU5 IBD Drug Market Forecasts ($m), 2015-2020
Table 5.7 EU5 IBD Drug Market Forecasts ($m), 2021-2026
Table 5.8 German IBD Drug Market Forecast ($m), 2015-2026
Table 5.9 French IBD Drug Market Forecast ($m), 2015-2026
Table 5.10 UK IBD Drug Market Forecast ($m), 2015-2026
Table 5.11 Spanish IBD Drug Market Forecast ($m), 2015-2026
Table 5.12 Italian IBD Drug Market Forecast ($m), 2015-2026
Table 5.13 BRIC IBD Drug Market Forecasts ($m), 2015-2020
Table 5.14 BRIC IBD Drug Market Forecasts ($m), 2021-2026
Table 5.15 Brazilian IBD Drug Market Forecast ($m), 2015-2026
Table 5.16 Russian IBD Drug Market Forecast ($m), 2015-2026
Table 5.17 Indian IBD Drug Market Forecast ($m), 2015-2026
Table 5.18 Chinese IBD Drug Market Forecast ($m), 2015-2026
Table 6.1 Selected IL Inhibitors in Clinical Development, 2015
Table 6.2 Selected CAM Inhibitors in Clinical Development, 2015
Table 6.3 Selected TNF-α Inhibitors in Clinical Development, 2015
Table 6.4 Selected Stem Cell Therapies in Clinical Development, 2015
Table 6.5 Selected JAK Inhibitors in Clinical Development, 2015
Table 6.6 Selected Toll-like Receptor Agonist in Clinical Development, 2015
Table 6.7 Selected Other Classes in Clinical Development, 2015
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2016
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2016
Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2014
Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2014
Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2014
Table 8.4 Allergan Revenues ($m) and Market Share (%), 2014
Table 8.5 Shire Revenues ($m) and Market Share (%), 2014
Table 10.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2014, 2020, 2026
Table 10.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2014, 2020, 2026
Table 10.3 Summary of IBD Market Drivers and Restraints, 2016-2026

List of Figures
Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016
Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2014
Figure 3.2 Global IBD Drug Market Forecast ($m), 2015-2026
Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2026
Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2015-2026
Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2015-2026
Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2015-2026
Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2015-2026
Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2015-2026
Figure 4.1 World Humira Revenue Forecast ($m), 2015-2026
Figure 4.2 World Remicade Forecast ($m), 2015-2026
Figure 4.3 World Asacol Forecast ($m), 2015-2026
Figure 4.4 World Pentasa Forecast ($m), 2015-2026
Figure 4.5 World Lialda Forecast ($m), 2015-2026
Figure 4.6 World Tysabri Forecast ($m), 2015-2026
Figure 4.7 World Xifaxan Forecast ($m), 2015-2026
Figure 4.8 World Cimzia Forecast ($m), 2015-2026
Figure 4.9 World Entocort Forecast ($m), 2015-2026
Figure 4.10 World Neoral Forecast ($m), 2015-2026
Figure 4.11 World Medrol Forecast ($m), 2015-2026
Figure 4.12 World Canasa Forecast ($m), 2015-2026
Figure 4.13 World Apriso Forecast ($m), 2015-2026
Figure 4.14 World Azulfidine Forecast ($m), 2015-2026
Figure 4.15 World Entyvio Forecast ($m), 2015-2026
Figure 4.16 World Simponi Forecast ($m), 2015-2026
Figure 4.17 World Uceris Forecast ($m), 2015-2026
Figure 5.1 Global IBD Drug Market by Leading Country (%), 2014
Figure 5.2 Global IBD Drug Market by Leading Country (%), 2026
Figure 5.3 US IBD Drug Market Forecast ($m), 2015-2026
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2015-2026
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2015-2026
Figure 5.6 German IBD Drug Market Forecast ($m), 2015-2026
Figure 5.7 French IBD Drug Market Forecast ($m), 2015-2026
Figure 5.8 UK IBD Drug Market Forecast ($m), 2015-2026
Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2015-2026
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2015-2026
Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2015-2026
Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2015-2026
Figure 5.13 Russian IBD Drug Market Forecast ($m), 2015-2026
Figure 5.14 Indian IBD Drug Market Forecast ($m), 2015-2026
Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2015-2026
Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2014

【レポートのキーワード】

炎症性腸疾患(IBD)、炎症性腸疾患治療薬、医薬品

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[炎症性腸疾患(IBD)治療薬の世界市場2016-2026]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月06日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆